MMP-7,
CCL18, SP-A, and SP-D were measured by commercially available enzyme-linked immunosorbent assay (ELISA) kits (Human Total MMP-7 Quantikine ELISA Kit, R&D Systems, MN; Human CCL18/PARC Quantikine ELISA Kit, R&D Systems, MN; SP-A Test Kokusai-F Kit, Sysmex, Japan; and SPD EIA Kit Yamasa, Yamasa, Japan).
Involvement of CC chemokine ligand 18 (
CCL18) in normal and pathological processes.
Although we did not detect any SNP associated with either oxidative DNA damage or IUGR, in univariate analysis we found four genes (MBL2, CCL7, CCL11, and
CCL18) modifying the incidence of LBW.
DCM did not induce spontaneous expression of M1 (iNOS, CD86, and TNF-[alpha]; Figures 4(d), 4(e), and 4(f)) or M2 markers {arginase 1 (Arg1) and CC motif ligand 18 (
CCL18); Figures 4(g) and 4(h)} in NR8383 cells.
They express IL-1 receptor antagonist (IL-1ra) and secrete
CCL18, transforming growth factor [beta] (TGF-[beta]), and remodelling enzymes.
Classification Number Cytokines Panel 1 6 TNF-RII, IL19, CCL5/RANTES, MIF, MPO, Galectin-3bp Panel 2 1 IL-23 IFN/gamma, TNF/alpha, TNF/RI, GM/CSF, Panel 3 37 IL/1 beta, IL/1ra, IL1/RII, IL2, IL2 R alpha, IL4, IL5, IL6, IL6R alpha, CXCL8/ IL8, IL10, IL/15, IL17A, IL22, CCL2, CCL4, CCL7, CCL11, CCL13,
CCL18, CCL22, CCL27, CXCL1/GRO alpha, CXCL4, CXCL10, CXCL12/SDF-1 alpha, CXCL13, CD14, CD27, CD30, CD40, NCAM-1/CD56, B7-H1/PD-L1/ CD274 Table 2: The outcomes of monkeys infected with M.
Laplante et al., "
CCL18 from ascites promotes ovarian cancer cell migration through proline-rich tyrosine kinase 2 signaling," Molecular Cancer, vol.
The chemokine
CCL18, which reflects the amount of macrophage activation, and chitotriosidase are both indicative of disease severity and the response of Gaucher patients to ERT.
A wide variety of proinflammatory mediators in COPD (like CXCL8, IL-6, and
CCL18) overlap with CF-related mediators [74, 81].
Although there is a high variation among patients, increased levels of IL-1[alpha], IL-1[beta], IL-1Ra, sIL-2R, IL-6, IL-8, IL-10, IL-18, TNF-[alpha], TGF-[beta], M-CSF, MIP-1, and
CCL18 have been reported in sera [39-41].
Pfeiffer, "
CCL18 is expressed in patients with bullous pemphigoid and paralells disease course," The British Journal of Dermatology, vol.
Recently, Chen and colleagues [48] linked TAM-produced
CCL18 with cancer cell invasiveness and identified PITPNM3 (a membrane-associated phosphatidylinositol transfer protein) as its receptor.